Research.Patient.info

Mycosis fungoides/Sezary syndrome recurrent research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic exploratory (Phase II)
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Spain · France